Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Grace Therapeutics cash
Cash and short-term investments held at the end of each period.
Grace Therapeutics's cash was $21.31M at Sep 30, 2026. For fiscal 2026 it was $16.98M, down 23.3% from the year before. The highest annual figure on record is $60.70M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $16.98M | -23.3% |
| FY2025 | Mar 31, 2025 | $22.13M | -3.8% |
| FY2024 | Mar 31, 2024 | $23.01M | -17.5% |
| FY2023 | Mar 31, 2023 | $27.89M | -36.1% |
| FY2022 | Mar 31, 2022 | $43.66M | -28.1% |
| FY2021 | Mar 31, 2021 | $60.70M | +326.3% |
| FY2020 | Mar 31, 2020 | $14.24M | -44.7% |
| FY2019 | Mar 31, 2019 | $25.76M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $21.31M | +1025.8% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $13.76M | +617.2% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $16.98M | -23.3% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $18.67M | +2133.5% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.89M | +83.3% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.92M | -37.2% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $22.13M | -3.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $836.00K | -90.3% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.03M | -90.3% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $3.06M | -43.7% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $23.01M | -17.5% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $8.63M | -72.4% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $10.61M | -69.6% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $5.43M | -85.9% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $27.89M | -36.1% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $31.26M | -32.5% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $34.94M | -31.2% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $38.39M | -33.5% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $43.66M | -28.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $46.33M | +66.0% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $50.79M | +737.6% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $57.70M | +994.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $60.70M | +326.3% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $27.90M | +305.9% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $6.06M | +131.9% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $5.27M | +373.5% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $14.24M | -44.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $6.87M | +7.0% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $2.62M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $1.11M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $25.76M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $6.42M | – |
See a number that looks wrong?